Clin Osteol 2019; 24(2): 53-56

Calcitonin: hormone into oblivionReview articles

Broulík Petr
III. interní klinika 1. LF UK a VFN v Praze

Calcitonin is 32-aminoacids polypeptide whose primary function is to inhibit osteoclasts activated bone resorption. In mammals is secreted in the thyroid gland specialized cells called C cells which have embrygenic origin in ultimobranchial bodies. C cells are about 0.1 % of the mass of thyroid gland. To achieve hypocalcemic effect is necessary all 32 aminoacids. Calcitonin is released from thyroid gland first of all by calcium and magnesium. Calcitonin is decreasing bone resorption which can demonstrated in vivo and in vitro. Calcitonin has been used to treat osteoporosis and algodystrophic syndrome. It had a lot of studies with good results on bone mineral density and fracture rate. The benefit-risk balance in the post-menopausal osteoporosis indication that the CHMP considered negative and recommended the withdrawal from the market of all products authorized only in this single indication across the European Union. Intracranialy calcitonin act as a neurotransmiter

. Prevailing opinion is view that calcitonin protects the skeleton under conditions of increased calcium demand as happens in times of growth, pregnancy and lactation. Calcitonin is also important tumor marker of thyroid carcinoma.

Keywords: osteoporosis; C-cells; calcitonin; calcium; magnesium; thyroid gland

Received: July 10, 2019; Accepted: August 15, 2019; Published: December 11, 2019  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Broulík P. Calcitonin: hormone into oblivion. Clinical Osteology. 2019;24(2):53-56.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Kumar MA. Foster GV, Macintyre I. Further evidence for calcitonin a rapid acting hormone which lowers plasma calcium. Lancet 1963; 2(7306): 480-482. Dostupné z DOI: <http://dx.doi.org/10.1016/s0140-6736(63)90224-1>. Go to original source...
    2. Struthers AD, Brown MJ, MacDonald DW et al. Human calcitonin gene related peptide: a potent endogenous vasodilator in man. Clin Sci (Lond) 1986; 70(4): 389-393. Go to original source...
    3. Blahoš J. Kalcitonin a fosfokalciový metabolismus. Jeho fyziologický a klinický význam. Avicenum: Praha 1974.
    4. Austin LA, Heath H. Physiology and pathophysiology of calcitonin. N Engl J Med 198l; 304(5): 269-278. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJM198101293040505>.
    5. Blahoš J, Zamrazil V (eds). Endokrinologie: Interdisciplinární obor. Triton: Praha 2006 : 112-114. ISBN 80-7254-788-7.
    6. Broulik P. Kalcitonin a jeho úloha v regulaci kalciofosfátového metabolismu. Ćas Lek Česk 2010; 149(6): 285-287.
    7. Moonga BS, Alam AS, Bevis PJ et al. Regulation of cytosolic free calcium in isolated osteoclasts by calcitonin. J Endocrinol 1992; 132(2): 241-249. Dostupné z DOI: <http://dx.doi.org/10.1677/joe.0.1320241>. Go to original source...
    8. Del Fattore A, Teti A,Rucci N. Osteoclast receptors and signaling. Arch Biochem Biophys 2008; 473(2): 147-160. Dostupné z DOI: <http://dx.doi.org/10.1016/j.abb.2008.01.011>. Go to original source...
    9. Chambers TJ, Hall TJ. Cellular and molecular mechanisms in the regulation and function of osteoclasts. Vitam Horm 1991; 46 : 41-86. Go to original source...
    10. Blahoš J, Care AD, Sommerville A. The effect of betamethazone on duodenal calcium absorption and 1,25-dihydroxyvitamine D production in the chick. Horm Metab Res 1983; 15(4): 197-200. Dostupné z DOI: <http://dx.doi.org/10.1055/s-2007-1018668>. Go to original source...
    11. Buclin T, Randin, JP, Jacquet AF et al. The effect of rectal and nasal administration of salomon calcitonin in normal subjects. Calcif Tissue Int 1987; 41(5): 252-258. Dostupné z DOI: <http://dx.doi.org/10.1007/bf02555225>. Go to original source...
    12. Wimalawansa SJ. Amylin, calcitonin gene-related peptide, calcitonin, and adrenomedullin: a peptide superfamily. Crit Rev Neurobiol 1997; 11(2-3): 167-239. Go to original source...
    13. Yoshimura M. Analgesic mechanism of calcitonin. J Bone Miner Metab 2000; 18(4): 230-233. Go to original source...
    14. Chesnut CH, Silverman S, Andriano K et al. A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study. Am J Med 2000; 109(4): 267-276. Go to original source...
    15. Chesnut CH, Majumdar S, Newitt DC et al. Effects of salmon calcitonin on trabecular microarchitecture as determined by magnetic resonance imaging:results from the QUEST study. J Bone Miner Res 2005; 20(9): 1548-1561. Dostupné z DOI: <http://dx.doi.org/10.1359/JBMR.050411>. Go to original source...
    16. Muller B, Becker KL, Schachinger H et al. Calcitonin precursors are reliable markers of sepsis in medical intensive care units. Crit Care Med 2000; 28(4): 977-983. Dostupné z DOI: <http://dx.doi.org/10.1097/00003246-200004000-00011>. Go to original source...
    17. Sato K, Hirata Y, Imai T et al. Characterization of immunoreactive adrenomedullin in human plasma and urine. Life Science 1995; 57(2): 189-194. Dostupné z DOI: <http://dx.doi.org/10.1016/0024-3205(95)00259-9>. Go to original source...
    18. Davey RA, Findlay DM. Calcitonin: Physiology or fantasy? J Bone Miner Res. 2013; 28(5): 973-979. Dostupné z DOI: <http://dx.doi.org/10.1002/jbmr.1869>. Go to original source...
    19. Blahoš J. Osteoporóza. Galén: Praha 1995. ISBN 8085824264.
    20. Kovacs CS. Calcium and bone metabolism during pregnancy and lactation. J Mammary Gland Biol Neoplasia 2005; 10(2): 105-118. Dostupné z DOI: <http://dx.doi.org/10.1007/s10911-005-5394-0>. Go to original source...
    21. Sexton PM, Findlay DM, Martin TJ. Calcitonin. Curr Med Chem 1999; 6(11): 1067-1093. Go to original source...
    22. Findlay DM, Sexton PM. Calcitonin. Growth Factors 2004;22(4):217-224. Dostupné z DOI: <http://dx.doi.org/10.1080/08977190410001728033>. Go to original source...
    23. Papi G, Corsello SM, Cioni K et al. Value of routine measurement of serum calcitonin concentrations in patients with nodular thyroid disease: A multicenter study. J Endocrinol Invest 2006; 29(5): 427-437. Dostupné z DOI: <http://dx.doi.org/10.1007/BF03344126>. Go to original source...

    Return to the content


    Clinical Osteology

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.